Based on evaluation of the currently available data and the scientific discussion within the Committee and at the CHMP’ s Blood Products Working Party, the CHMP concluded that the benefits of Uman Big outweigh its risks, and that therefore the marketing authorisation for Uman Big should be granted in all concerned member states.